234 related articles for article (PubMed ID: 7748196)
1. Agonist properties of a stable hexapeptide analog of neurotensin, N alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1).
Akunne HC; Demattos SB; Whetzel SZ; Wustrow DJ; Davis DM; Wise LD; Cody WL; Pugsley TA; Heffner TG
Biochem Pharmacol; 1995 Apr; 49(8):1147-54. PubMed ID: 7748196
[TBL] [Abstract][Full Text] [Related]
2. Functional activity of new C-terminal cyclic-neurotensin fragment analogs.
Akunne HC; Darling S; Zoski K; Sefler AM; He JX; Sawyer TK; Pugsley TA; Cody WL
Neuropeptides; 1996 Jun; 30(3):213-8. PubMed ID: 8819144
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists.
Pugsley TA; Akunne HC; Whetzel SZ; Demattos S; Corbin AE; Wiley JN; Wustrow DJ; Wise LD; Heffner TG
Peptides; 1995; 16(1):37-44. PubMed ID: 7716073
[TBL] [Abstract][Full Text] [Related]
4. Neurotensin receptors on the rat liver plasma membranes.
Muraki K; Nishi Y; Arai M; Kubo N; Ueda K; Shikata H; Nakata Y; Segawa T; Yanaihara N; Yajima H
Biochem Biophys Res Commun; 1987 Jun; 145(3):1071-9. PubMed ID: 3038090
[TBL] [Abstract][Full Text] [Related]
5. Neurotensin modulates the electrical activity of frog pituitary melanotropes via activation of a G-protein-coupled receptor pharmacologically related to both the NTS1 and nts2 receptors of mammals.
Belmeguenai A; Vaudry H; Leprince J; Vivet B; Cavelier F; Martinez J; Louiset E
Neuroendocrinology; 2000 Dec; 72(6):379-91. PubMed ID: 11146421
[TBL] [Abstract][Full Text] [Related]
6. LANT-6, xenopsin and neuromedin N stimulate cyclic GMP at neurotensin receptors.
Gilbert JA; Richelson E
Eur J Pharmacol; 1986 Oct; 129(3):379-83. PubMed ID: 3023108
[TBL] [Abstract][Full Text] [Related]
7. Activation of neurotensin receptors and purinoceptors in human colonic adenocarcinoma cells detected with the microphysiometer.
Richards M; van Giersbergen P; Zimmermann A; Lesur B; Hoflack J
Biochem Pharmacol; 1997 Oct; 54(7):825-32. PubMed ID: 9353137
[TBL] [Abstract][Full Text] [Related]
8. Human umbilical vein endothelial cells express high affinity neurotensin receptors coupled to intracellular calcium release.
Schaeffer P; Laplace MC; Savi P; Pflieger AM; Gully D; Herbert JM
J Biol Chem; 1995 Feb; 270(7):3409-13. PubMed ID: 7852427
[TBL] [Abstract][Full Text] [Related]
9. Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells.
Yamada M; Yamada M; Lombet A; Forgez P; Rostène W
Life Sci; 1998; 62(23):PL 375-80. PubMed ID: 9627096
[TBL] [Abstract][Full Text] [Related]
10. Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues.
Sefler AM; He JX; Sawyer TK; Holub KE; Omecinsky DO; Reily MD; Thanabal V; Akunne HC; Cody WL
J Med Chem; 1995 Jan; 38(2):249-57. PubMed ID: 7830267
[TBL] [Abstract][Full Text] [Related]
11. On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum--neurotensin, opiorphin, B27-KK10 epitope, NPY.
Seebach D; Lukaszuk A; Patora-Komisarska K; Podwysocka D; Gardiner J; Ebert MO; Reubi JC; Cescato R; Waser B; Gmeiner P; Hübner H; Rougeot C
Chem Biodivers; 2011 May; 8(5):711-39. PubMed ID: 21560227
[TBL] [Abstract][Full Text] [Related]
12. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
Labbé-Jullié C; Botto JM; Mas MV; Chabry J; Mazella J; Vincent JP; Gully D; Maffrand JP; Kitabgi P
Mol Pharmacol; 1995 May; 47(5):1050-6. PubMed ID: 7746272
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity and conformational studies of a series of modified C-terminal hexapeptide neurotensin analogues.
Heyl DL; Sefler AM; He JX; Sawyer TK; Wustrow DJ; Akunne HC; Davis MD; Pugsley TA; Heffner TG; Corbin AE
Int J Pept Protein Res; 1994 Sep; 44(3):233-8. PubMed ID: 7822099
[TBL] [Abstract][Full Text] [Related]
14. Neurotensin and neuromedin N elevate the cytosolic calcium concentration via transiently appearing neurotensin binding sites in cultured rat cortex cells.
Sato M; Shiosaka S; Tohyama M
Brain Res Dev Brain Res; 1991 Jan; 58(1):97-103. PubMed ID: 1849803
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes.
Labbé-Jullié C; Dubuc I; Brouard A; Doulut S; Bourdel E; Pelaprat D; Mazella J; Martinez J; Rostène W; Costentin J
J Pharmacol Exp Ther; 1994 Jan; 268(1):328-36. PubMed ID: 8301574
[TBL] [Abstract][Full Text] [Related]
16. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist.
Sarhan S; Hitchcock JM; Grauffel CA; Wettstein JG
Peptides; 1997; 18(8):1223-7. PubMed ID: 9396065
[TBL] [Abstract][Full Text] [Related]
17. Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain.
Betancur C; Canton M; Burgos A; Labeeuw B; Gully D; Rostène W; Pélaprat D
Eur J Pharmacol; 1998 Feb; 343(1):67-77. PubMed ID: 9551716
[TBL] [Abstract][Full Text] [Related]
18. Evidence for biological activity of two N-terminal fragments of neurotensin, neurotensin1-8 and neurotensin1-10.
Hernandez DE; Richardson CM; Nemeroff CB; Orlando RC; St-Pierre S; Rioux F; Prange AJ
Brain Res; 1984 May; 301(1):153-6. PubMed ID: 6329440
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier.
Bredeloux P; Cavelier F; Dubuc I; Vivet B; Costentin J; Martinez J
J Med Chem; 2008 Mar; 51(6):1610-6. PubMed ID: 18321036
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.
Gully D; Labeeuw B; Boigegrain R; Oury-Donat F; Bachy A; Poncelet M; Steinberg R; Suaud-Chagny MF; Santucci V; Vita N; Pecceu F; Labbé-Jullié C; Kitabgi P; Soubrié P; Le Fur G; Maffrand JP
J Pharmacol Exp Ther; 1997 Feb; 280(2):802-12. PubMed ID: 9023294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
